Article
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
Gut - 1 Jun 2014
Lai Ching-Lung, Ahn Sang Hoon, Lee Kwan Sik, Um Soon Ho, Cho Mong, Yoon Seung Kew, Lee Jin-Woo, Park Neung Hwa, Kweon Young-Oh, Sohn Joo Hyun, Lee Jiyoon, Kim Jeong-Ae, Han Kwang-Hyub, Yuen Man-Fung
Abstract excerpt
BACKGROUND: Besifovir (LB80380) is an acyclic nucleotide phosphonate effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies. DESIGN: We aimed to compare the safety and antiviral activity of t...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.